Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN-PEAK: Tominersen PK/PD Study in Huntington's Disease
NCT04000594Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2019
- Primary completion
- Jan 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 1, open-label trial of tominersen in Huntington's disease (HD) (3 arms), sponsored by Roche. Primary endpoints: Concentrations of RO7234292 in CSF, Concentrations of RO7234292 in Plasma and 1 more. Started Sep 2019; status: completed.
02
Drugs
tominersen
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT04000594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04000594.